Northeast Financial Consultants Inc Reduces Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)

Northeast Financial Consultants Inc reduced its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 41.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 42,953 shares of the company’s stock after selling 30,000 shares during the quarter. Northeast Financial Consultants Inc owned 0.05% of Immunome worth $456,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new stake in Immunome during the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS purchased a new position in Immunome during the fourth quarter valued at $75,000. AlphaQuest LLC grew its holdings in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its holdings in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new stake in Immunome in the fourth quarter worth about $95,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

NASDAQ IMNM opened at $7.91 on Wednesday. The company has a market capitalization of $688.26 million, a P/E ratio of -0.98 and a beta of 2.00. Immunome, Inc. has a one year low of $5.15 and a one year high of $16.81. The stock has a 50 day moving average price of $7.71 and a 200-day moving average price of $9.90.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The company had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.46 million. As a group, equities analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Transactions at Immunome

In other news, CTO Philip Tsai bought 12,300 shares of Immunome stock in a transaction dated Monday, March 24th. The shares were acquired at an average price of $8.42 per share, with a total value of $103,566.00. Following the completion of the purchase, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. The trade was a 58.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall bought 137,100 shares of the stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of $7.29 per share, with a total value of $999,459.00. Following the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. The trade was a 20.47% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 156,400 shares of company stock worth $1,160,495 in the last three months. Insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IMNM. Lifesci Capital initiated coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Stephens reiterated an “overweight” rating and issued a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Lake Street Capital initiated coverage on shares of Immunome in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price objective for the company. Wedbush restated an “outperform” rating and set a $21.00 target price (down previously from $33.00) on shares of Immunome in a research note on Tuesday. Finally, Guggenheim dropped their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $23.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.